Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have received a consensus rating of "Buy" from the eight research firms that are covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $41.20.
BCAX has been the topic of several recent research reports. Wedbush reiterated an "outperform" rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research note on Wednesday, February 12th. HC Wainwright lifted their target price on Bicara Therapeutics from $42.00 to $45.00 and gave the company a "buy" rating in a research report on Monday, January 27th. Rodman & Renshaw started coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They set a "buy" rating and a $48.00 price target for the company. Finally, RODMAN&RENSHAW raised Bicara Therapeutics to a "strong-buy" rating in a research report on Tuesday, November 5th.
Check Out Our Latest Stock Report on Bicara Therapeutics
Bicara Therapeutics Stock Up 2.7 %
Shares of BCAX traded up $0.36 during mid-day trading on Friday, hitting $13.48. 180,535 shares of the company's stock were exchanged, compared to its average volume of 352,690. The stock has a 50-day moving average of $14.83. Bicara Therapeutics has a 52 week low of $11.10 and a 52 week high of $28.09.
Institutional Trading of Bicara Therapeutics
Hedge funds have recently made changes to their positions in the business. Spire Wealth Management bought a new position in Bicara Therapeutics in the 4th quarter valued at about $31,000. BNP Paribas Financial Markets acquired a new position in shares of Bicara Therapeutics in the fourth quarter valued at approximately $32,000. Legal & General Group Plc acquired a new position in shares of Bicara Therapeutics in the fourth quarter valued at approximately $33,000. Summit Investment Advisors Inc. bought a new position in shares of Bicara Therapeutics during the fourth quarter worth approximately $35,000. Finally, Virtus ETF Advisers LLC acquired a new stake in Bicara Therapeutics during the 4th quarter worth approximately $69,000.
About Bicara Therapeutics
(
Get Free ReportBicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Further Reading
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
